Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 19/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2159527 | 1.00 | CCR1 (0.69) | CCR1NR1I2LMNATSHRKMT2A | |
| SCHEMBL2159586 | 0.88 | CCR1 (0.74) | CCR1NR1I2KMT2A | |
| SCHEMBL2159581 | 0.88 | CCR1 (0.74) | CCR1NR1I2KMT2A | |
| SCHEMBL2159153 | 0.85 | CCR1 (0.78) | CCR1NR1I2 | |
| SCHEMBL2159148 | 0.85 | CCR1 (0.78) | CCR1NR1I2 | |
| SCHEMBL10292006 | 0.84 | CCR1 (0.73) | CCR1NR1I2 | |
| SCHEMBL2160692 | 0.82 | CCR1 (1.00) | CCR1NR1I2 | |
| SCHEMBL2160698 | 0.82 | CCR1 (1.00) | CCR1NR1I2 | |
| SCHEMBL10292298 | 0.82 | CCR1 (0.82) | CCR1NR1I2 | |
| SCHEMBL10292241 | 0.81 | CCR1 (0.78) | CCR1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985861-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-26 | — | — | US | disclosed |
| US-20090298833-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
| EP-2049486-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007092681-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298833-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | CCR1 1/4885NR1I2 101/4885LMNA 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.